Antiviral effects of milk proteins: Acylation results in polyanionic compounds with potent activity against human immunodeficiency virus types 1 and 2 in vitro

AIDS Research and Human Retroviruses

Volumn 12, Issue 9, 1996, Pages 769-775

  Swart, P J ^a   Kuipers, M E ^a   Smit, C ^a   Pauwels, R ^b,c   De Bethune M P ^b,c   De Clercq, E ^b   Meijer, D K F ^a   Huisman, J G ^d  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c TIBOTEC BVBA   (Belgium)

^d CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA LACTALBUMIN; BETA LACTOGLOBULIN; LACTOFERRIN; POLYANION;

ACYLATION; ANTIVIRAL ACTIVITY; ARTICLE; CELL FUNCTION; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FOLDING; VIRUS CELL INTERACTION; VIRUS INFECTION;

EID: 0029892820     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.769     Document Type: Article

References (32)

1. Baba M, Pauwels P, Balzarini J, Arnout J, Desmyter J, and De Clercq E: Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci USA 1988;85:6132-6136.
2. + cells. Science 1988;240: 646-649.
3. Mbemba E, Czyrski JA, and Gattegno L: The interaction of a glycosaminoglycan, heparin, with HIV-1 major envelope glycoprotein. Biochim Biophys Acta 1992;1180:123-129.
4. Jansen RW, Molema G, Pauwels R, Schols D, De Clercq E, and Meijer DKF: Potent in vitro anti-human immunodeficiency virus-1 activity of modified human serum albumins. Mol Pharmacol 1991;39:818-823.
5. Jansen RW, Schols D, Pauwels R, De Clercq E, and Meijer DKF: Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity. Mol Pharmacol 1993;44:1003-1007.
6. Dalgleish AG: How human immunodeficiency virus enters cells: Implications for pathogenesis. In: Membrane Interactions of HIV. Wiley-Liss, 1992, pp. 15-32.
7. Nilsson K and Mosbach K: Immobilization of enzymes and affinity ligands to various hydroxyl group carrying supports using highly reactive sulfonyl chlorides. Biochem Biophys Res Commun 1981;102:449-157.
8. Kuipers ME, Huisman JG, Swart PJ, de Béthune M, Pauwels R, De Clercq E, Schuitemaker H, and Meijer DKF: Mechanism of anti-HIV activity of negatively charged albumins: Biomolecular interaction with the HIV-1 envelope protein gp120. J Acquir Immune Defic Syndr 1995 (in press).
9. Groenink M, Swart PJ, Broersen S, Kuipers M, Meijer DKF, and Schuitemaker H: Potent inhibition of replication of primary HIV-1 isolates by negatively charged human serum albumin. AIDS Res Hum Retroviruses (submitted).
10. Jansen RW, Olinga P, Harms G, and Meijer DKF: Pharmacokinetic analysis and cellular distribution of the anti-HIV compound succinylated human serum albumin (Suc-HSA) in vivo and in the isolated perfused rat liver. Pharm Res 1993; 10:1611-1614.
11. Swart PJ and Meijer DKF: Negatively-charged albumins: A novel class of polyanionic proteins with a potent anti-HIV activity. Antiviral News 1994;2:69-71.
12. Matthews THJ, Lawrence MK, Nair CDG, and Tyrrell DAJ: Antiviral activity in milk of possible clinical importance. Lancet 1976; December 25:1378-1389.
13. Gold P: Method of treatment of HIV-seropositive individuals with dietary whey proteins. 1994:1-18;PCT/CA93/00107 (Application number); WO 93/20831 (patent number).
14. Newburg DS, Viscidi RP, Ruff A, and Yolken RH: A human milk factor inhibits binding of human immunodeficiency virus to the CD4 receptor. Pediatr Res 1992;33:22-28.
15. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193:265-275.
16. Habeeb AFSA: Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem 1966;14:328-336.
17. Miyoshi I, Taguchi H, Kubonishi I, Yoshimoto S, Ohtsuki Y, Shiraishi Y, and Akagi T: Type C virus-producing cell lines derived from adult T cell leukemia. Gann Monogr Cancer Res 1982;28:219-228.
18. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J, and De Clercq E: Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988;20:309-321.
19. Pless DP and Lennarz WJ: Enzymatic conversion of proteins to glycoproteins. Proc Natl Acad Sci USA 1977;74:134-138.
20. 131I labelled human growth hormone of high specific radioactivity. Biochem J 1963;89:114-123.
21. Harmsen MC, Swart PJ, de Béthune M, Pauwels R, De Clercq E, de Thé TH, and Meijer DKF: Antiviral effects of plasma and milk proteins: Lactoferrin shows potent antiviral activity on both human immunodeficiency virus and human cytomegalovirus. J Infect Dis 1995;172:380-388.
22. Mbemba E, Chams V, Gluckman JC, Klatzmann D, and Gattegno L: Molecular interaction between HIV-1 major envelope glycoprotein and dextran sulfate. Biochim Biophys Acta 1992; 1138:62-67.
23. Batinic D and Robey FA: The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides. J Biol Chem 1992;267:6664-6671.
24. Meshcheryakova D, Andreev S, Tarasova S, Sidorova M, Vafina M, Kornilaeva G, Karamov E, and Khaitov R: CD4-derived peptide and sulfated polysaccharides have similar mechanisms of anti-HIV activity based on electrostatic interactions with positively charged gp120 fragments. Mol Immunol 1993;30:993-1001.
25. Kamimoto Y, Tanabe D, Tashiro S, Hiraoka T, and Miyauchi Y: Changes in receptor-mediated endocytosis in liver sinusoidal cells after partial hepatectomy in the rat. Liver 1994;14:141-147.
26. Cardin AD, Taylor DL, Krstenansky JL, Tyms AS, and Jackson RL: A heparin which binds to the envelope glycoprotein gp120 inhibits human immunodeficiency virus replication. Trans Assoc Am Physicians 1989;102:101-109.
27. Jackson RL, Busch SJ, and Cardin AD: Glycosaminoglycans: Molecular properties, protein interactions, and role in physiological processes. Physiol Rev 1991;71:481-539.
28. Witvrouw M, Desmyter J, and De Clercq E: Antiviral portrait series. 4. Polysulfates as inhibitors of HIV and other enveloped viruses. Antiviral Chem Chemother 1994;5:345-359.
29. Yahi N, Sabatier JM, Nickel P, Mabrouk K, Gonzalezscarano F, and Fantini J: Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells. J Biol Chem 1994;269:24349-24353.
30. Lazanas MC, Tsekes GA, Papandreou S, Harhalakis N, Scandali A, Nikiforakis E, and Saroglou G: Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds. AIDS 1993;7:1018-1019.
31. Day CL, Anderson BF, Tweedie JW, and Baker EN: Structure of the recombinant N-terminal lobe of human lactoferrin at 2.0-angstrom resolution. J Mol Biol 1993;232:1084-1100.
32. Anderson BF, Baker HM, Norris GE, Rice DW, and Baker EN: Structure of human lactoferrin: Crystallographic structure analysis and refinement at 2.8 Å resolution. J Mol Biol 1989;209:711-734.